Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
signs and symptoms pathological conditions | D013568 |
Brand Name | Status | Last Update |
---|---|---|
banzel | New Drug Application | 2022-12-17 |
rufinamide | ANDA | 2025-03-05 |
rufinamide rufinamide | ANDA | 2023-05-17 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lennox gastaut syndrome | D065768 | — | G40.81 | — | — | 3 | — | 3 | 6 |
Syndrome | D013577 | — | — | — | — | 2 | — | 3 | 5 |
Seizures | D012640 | — | G40.4 | — | — | 2 | — | — | 2 |
Complex partial epilepsy | D017029 | EFO_1000877 | — | — | — | 1 | — | — | 1 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | 1 | — | — | 1 |
Drug common name | Rufinamide |
INN | rufinamide |
Description | Rufinamide is a heteroarene and an aromatic amide. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | NC(=O)c1cn(Cc2c(F)cccc2F)nn1 |
PDB | — |
CAS-ID | 106308-44-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1201754 |
ChEBI ID | — |
PubChem CID | 129228 |
DrugBank | — |
UNII ID | WFW942PR79 (ChemIDplus, GSRS) |